Version Changes
Revised. Amendments from Version 2
In the current version, we provide previous research that corroborates our hypothesis that helices with characteristically unique properties are involved in host protein interactions. Specifically, 3FKEA.HELIX2 from VP35, 4U2XA.HELIX7 from VP24 and 3FKEA.HELIX1 from VP35 are shown to have significance in the viral protein interactions. Fig.3d and Table 5 (with a corresponding shift in the subsequent table numbering) are additional in this version.
Abstract
Ebola, considered till recently as a rare and endemic disease, has dramatically transformed into a potentially global humanitarian crisis. The genome of Ebola, a member of the Filoviridae family, encodes seven proteins. Based on the recently implemented software (PAGAL) for analyzing the hydrophobicity and amphipathicity properties of alpha helices (AH) in proteins, we characterize the helices in the Ebola proteome. We demonstrate that AHs with characteristically unique features are involved in critical interactions with the host proteins. For example, the Ebola virus membrane fusion subunit, GP2, from the envelope glycoprotein ectodomain has an AH with a large hydrophobic moment. The neutralizing antibody (KZ52) derived from a human survivor of the 1995 Kikwit outbreak recognizes a protein epitope on this AH, emphasizing the critical nature of this secondary structure in the virulence of the Ebola virus. Our method ensures a comprehensive list of such `hotspots'. These helices probably are or can be the target of molecules designed to inhibit AH mediated protein-protein interactions. Further, by comparing the AHs in proteins of the related Marburg viruses, we are able to elicit subtle changes in the proteins that might render them ineffective to previously successful drugs. Such differences are difficult to identify by a simple sequence or structural alignment. Thus, analyzing AHs in the small Ebola proteome can aid rational design aimed at countering the `largest Ebola epidemic, affecting multiple countries in West Africa' ( http://www.cdc.gov/vhf/ebola/outbreaks/2014-west-africa/index.html).
Introduction
The Ebola virus was first discovered in 1976 1, and has been since known as a rare, but deadly disease 2. However, the current outbreak in West African countries (Guinea, Liberia, Nigeria, Sierra Leone and Senegal) has rapidly deteriorated into a full blown epidemic 3, and poses grave humanitarian dangers to these countries 4. Ebola, along with the Marburg virus, belongs to the Filoviridae family 5, and causes haemorrhagic fever 2 by quickly suppressing innate antiviral immune responses to facilitate uncontrolled viral replication 6.
Interestingly, the genome of the Ebola virus encodes seven proteins 7, although their extreme ‘plasticity allows multiple functions’ 8, 9. Protein structures are formed by well ordered local segments, of which the most prevalent are alpha helices (AH) and β sheets. AHs are right-handed spiral conformations which have a hydrogen bond between the carbonyl oxygen (C=O) of each residue and the alpha-amino nitrogen (N-H) of the fourth residue away from the N-terminal. AH domains are often the target of peptides designed to inhibit viral infections 10– 12. Recently, we have provided open access to software that has reproduced previously described computational methods 13 to compute the hydrophobic moment of AHs (PAGAL 14).
In the current work, we characterize the helices in the Ebola proteome using PAGAL, and demonstrate that the helices with characteristically unique feature values are involved in critical interactions with the host proteins. The PDB database is queried for the keyword ‘Ebola’, and the structures obtained are analyzed using DSSP 15 for identifying AHs. We process all PDB structures, and do not filter out redundant structures based on sequence. These helices are analyzed using PAGAL, and the results are sorted based on three criteria - hydrophobic moment and high proportion of positive or negative residues. The helices that are ranked highest in these sorting criteria are involved in critical interactions with either antibodies or host proteins. For example, the Ebola virus membrane fusion subunit, GP2, from the envelope glycoprotein ectodomain has an AH with the largest hydrophobic moment in all helices analyzed 16. This helix has part of the epitope recognized by the neutralizing antibody (KZ52) derived from a human survivor of the 1995 Kikwit outbreak, emphasizing the critical nature of this helix in the virulence of Ebola 17. Another example, obtained by choosing the helix with the highest proportion of negatively charged residues, is the interaction between the human karyopherin alpha nuclear transporters C terminus and the Ebola virus VP24 protein (eVP24) 18, which suppresses tyrosine-phosphorylated STAT1 nuclear import 19. These helices probably are, or can be, the target of molecules designed to inhibit AH mediated protein-protein interactions 20. Our method provides a comprehensive list of such targets. Further, each protein can be individually queried using PAGAL, and thus identify helices that might have a poor global rank, but still be critical in the particular proteins context.
Although, Ebola and Marburg viruses are members of the Filoviridae family 21, they have different antigenicity of the virion glycoprotein 22. By comparing the AHs in proteins of Marburg and Ebola viruses, we are able to elicit subtle changes in the proteins that might render them ineffective against previously successful drugs. These differences are not apparent from a simple sequence or structural alignment. Thus, in the current work, we elucidate a simple methodology that can aid rational design of drugs and vaccine, an important aspect of the global effort to counter the deadly Ebola epidemic.
Materials and methods
We searched for the keyword ‘Ebola’ in the PDB database ( Table 1). Subsequently, each protein was split based on the chain id, resulting in 146 single chained proteins (See ALPHA.zip in Dataset 1). We have not reduced the set based on sequence similarity since the proteins might have different conformations based on their ligands. Note, this list might include non-Ebola proteins which might have been co-crystallized with the Ebola protein. However, they have been put through the same analysis since they might provide insights into the Ebola proteins themselves.
Table 1. PDB ID of Ebola proteins analyzed.
PDB ID | Description |
---|---|
1EBO,2EBO,3VE0,3CSY..
2I8B,3V7O 3FKE,3L25,4LG2,4IBK... 3VNE,4D9O,4M0Q,4U2X.. 4QAZ,4QAZ 1ES6,1H2D,3TCQ,4LDM... |
Ebola virus envelope protein
Minor nucleoprotein VP30 Polymerase cofactor VP35 Membrane-associated protein VP24 Nucleoprotein Matrix protein VP40 |
These proteins were then analyzed using DSSP 15, and resulted in 758 helices in all (See ALPHA.zip in Dataset 1). These helices were then analyzed using PAGAL. The PAGAL algorithm has been detailed previously 14. Briefly, the Edmundson wheel is computed by considering a wheel with centre (0,0), radius 5, first residue coordinate (0,5) and advancing each subsequent residue by 100 degrees on the circle, as 3.6 turns of the helix makes one full circle. We compute the hydrophobic moment by connecting the center to the coordinate of the residue and give it a magnitude obtained from the hydrophobic scale (in our case, this scale is obtained from 13). These vectors are then added to obtain the final hydrophobic moment.
The color coding is as follows: all hydrophobic residues are colored red, while hydrophilic residues are colored in blue: dark blue for positively charged residues, medium blue for negatively charged residues and light blue for amides.
The raw file generated by analyzing all 146 proteins through PAGAL is provided as PAGALRAWDATA.txt ( Dataset 1), and contains the hydrophobic moment, percent of positive charges and the total number of charged residues for every helix. These are then sorted based on the charge (negative or positive) or the hydrophobic moment. We ignore the helices that have none or a single charged residue, and those that are smaller than 10 residues in length. The proportion of charged residues is computed based on the total number of charged residues, and not the length of the helix.
All protein structures were rendered by PyMol ( http://www.pymol.org/). The sequence alignment was done using ClustalW 23. The alignment images were generated using Seaview 24. Protein structures have been superimposed using MUSTANG 25.
Results and discussion
Helices with large hydrophobic moment
We began by analyzing the helices which have a large hydrophobic moment (hydrophobic scale is obtained from 13) ( Table 2). The Edmundson wheel for the helix 1EBOE.HELIX1 from the structure of GP2 from the Ebola virus membrane fusion glycoprotein (PDBid:1EBO) 16 is shown in Figure 1a. Figure 1b shows the residues comprising these helices (in magenta) in the apo form (PDBid:1EBO) 16. The neutralizing antibody (KZ52) derived from a human survivor of the 1995 Kikwit outbreak (PDBid:3CSY) 17 recognizes an epitope on this AH, emphasizing the critical nature of this AH in the virulence of the Ebola virus ( Figure 1c,d). The antibody most likely inhibits the rearrangement of GP2 segments, which abrogates the fusion of the internal loop in the host membrane 17. Table 3 shows the residues in the specified helix (residues 553-597, chain J, PDBid:3CSY) making possible hydrogen bonds with different residues in the human Fab KZ52 heavy chain (residues 1-228, chain A, PDBid:3CSY). Among all the interactions, only Gly553 is on 1EBOE.HELIX1 (at a distance of 2.7 Å from Thr100/OG1), although the others are sequentially proximal. These few interactions are sufficient to bind to this helix, rendering the virus non-virulent, and leading to human recovery. The importance of interfacial hydrophobicity in viral proteins involved in host entry through membrane fusion has recently been discussed in detail, and remains ‘an underutilized therapeutic target’ 26. 1EBOE.HELIX0 ( Table 2) also has a high hydrophobic moment, but is actually an isoleucine zipper derived from GCN4 27 ( Figure 1b).
Table 2. Identifying helices with unique properties.
Property | Protein | Helix | Len | HM | RPNR | NCH |
---|---|---|---|---|---|---|
HM | GP
GP |
1EBOE.HELIX1
1EBOE.HELIX0 |
46
29 |
16.2
11.5 |
0.5
0.5 |
11
13 |
NEG | VP24
VP35 |
4U2XA.HELIX5
3FKEA.HELIX2 |
16
14 |
4.4
3.2 |
0
0.2 |
2
4 |
POS | VP24
VP35 |
4U2XA.HELIX7
3FKEA.HELIX1 |
19
15 |
6.5
7.8 |
0.8
0.8 |
5
4 |
Table 3. Interactions obtained from the crystal structure of the Ebola virus glycoprotein in complex with a neutralizing antibody from a human survivor.
AtomEbola | AtomAntibody | Dist (Å) |
---|---|---|
ASP/552/OD1
GLY/553/N ASN/550/O ASP/552/OD1 ASN/550/ND2 ASN/550/ND2 ASP/552/OD2 |
SER/53/OG
THR/100/OG1 ASN/31/O SER/53/CB PRO/97/O ASN/31/O SER/53/OG |
2.5
2.7 2.9 2.9 3.0 3.2 3.2 |
Helices with high proportion of negatively charged residues. Identifying difference among related species
We then analyzed the helices having a high proportion of negatively charged residues, sorted based on the length of the helix when the percentage of negatively residues are the same ( Table 2). Figure 2a shows the Edmundson wheel for the helix 4U2XA.HELIX5 (which has only two charged residues - the basic E113 and D124), while Figure 2b,c shows this helix in the protein complex marked in magenta. Note, that we exclude AHs with either zero or one charged residues (see Methods). Protein PDBid:4U2XD is the human karyopherin alpha nuclear transporter (KPNA) C terminus in complex with the Ebola virus VP24 protein (eVP24) 18. eVP24 interferes with the immune response by selectively targeting tyrosine-phosphorylated STAT1 nuclear import 19. It does not hinder the transport of other cargo that may be required for viral replication. 4U2XA.HELIX5 is responsible for forming the complex with the KPNA protein through a helix (4U2XD.HELIX9, in blue), and K481 from KPNA is in contact with D124 from eVP24 (distance between K481/NZ and D124/OD2 is 3.98 Å). Their interaction is probably electrostatic, since the atoms have opposite charges. VP24 has also been shown to directly bind to STAT1, further compromising the immune response 28. Recently, KPNA was docked to Reston Ebola VP24 (PDBid:4D9OA) 28 using the VP24 from Zaire Ebola (PDBid:4U2XA) 18 as a template 29. The docked structure showed that a single mutation might be one of the critical factors responsible for the non-pathogenic nature of Reston Ebola in humans 30, 31. Also, it was shown that the VP24 from Marburg virus (PDBid:3VNEA) 28, which has a different immunosuppressive mechanism than the Ebola virus 32, has different properties in the helices responsible for binding KPNA in the Zaire Ebola VP24.
The next helix having a high proportion of negatively charged residues (3FKEA.HELIX2) is from a VP35, a classic example of a moonlighting protein, that can be a component of the viral RNA polymerase complex, a viral assembly factor, or inhibitor of host interferon production 33. This helix is part of the dsRNA-binding domain of VP35 that is involved in the formation of the asymmetric VP35 RBD dimeric interface in Reston Ebola virus through a hydrogen-bonding network of residues and a solvent molecule 34. Interestingly, this helix is homologous (100.0% similar and 78% identity in 9 amino acid overlap) to helix ‘1A’ of an ATP-dependent transcriptional activator 35. This helix interacts with another ‘1B’ helix from a different monomer in an anti-parallel fashion to facilitate dimerization.
VP35 consists of several helices, and is reasonably conserved in the Marburg virus from the same Filoviridae family (42% identity, 58% similarity) ( Figure 3a). Often, it is difficult to identify the regions of the protein that differ from a sequence or structural alignment ( Figure 3b), in case there is interest in understanding different responses of the proteins to known drugs or even the immune system. Table 4 compares the characteristics of the helices in the VP35 from Ebola and Marburg (the helix numbering is offset by one, due to a small N-terminal helix in the Marburg protein (which might be due to crystallization technique differences and probably is not critical). Thus, we have numbered these helices using alphabets. It can be seen that most of the helices have the same properties, barring helices E and F, where the acidic residue is present in the E helix in Marburg and in the F helix in Ebola. These helices are marked in yellow in Figure 3b. Also, it can be seen that helix C, which has a high proportion of acidic residues in VP35, has a fewer number of those residues in Marburg. The difference in the pathogenicity of these viruses are encoded in the structure of the expressed proteins, and the design of drugs and vaccines to counter virulence should take these differences into account.
Table 4. Detecting differences in related proteins based on characteristics of alpha helices.
Helix Name | Real Helix | Len | HM | RPNR | NCH |
---|---|---|---|---|---|
A | 4GHLA.HELIX1
3FKEA.HELIX0 |
10
9 |
2.8
5 |
0.5
0.7 |
2
3 |
B | 4GHLA.HELIX2
3FKEA.HELIX1 |
15
15 |
5.3
7.8 |
1
0.8 |
3
4 |
C | 4GHLA.HELIX3
3FKEA.HELIX2 |
13
14 |
4.6
3.2 |
0.5
0.2 |
2
4 |
D | 4GHLA.HELIX4
3FKEA.HELIX3 |
11
11 |
5.1
3.6 |
1
1 |
2
2 |
E
|
4GHLA.HELIX5
3FKEA.HELIX4 |
3
3 |
2.7
1.1 |
0
-1 |
1
0 |
F | 4GHLA.HELIX6
3FKEA.HELIX5 |
3
3 |
1
1.3 |
-1
0.5 |
0
2 |
G | 4GHLA.HELIX7
3FKEA.HELIX6 |
6
6 |
4.7
4.7 |
1
1 |
2
2 |
H | 4GHLA.HELIX8
3FKEA.HELIX7 |
3
3 |
2.8
3.4 |
0.5
0.5 |
2
2 |
Helices with high proportion of positively charged residues
4U2XA.HELIX7 from VP24 is a helix having a high proportion of positively charged residues ( Table 2), and contains two (L147P and R154L) of three mutations (L147P, M71I and R154L) that sensitizes guinea pigs to the Zaire Ebola virus 36. This helix is marked in yellow in Figure 2c. The second helix (3FKEA.HELIX1) is from VP35, which was discussed previously 33. This helix spans residues 238-252 and includes Lys248 and Lys251, a basic patch which is ‘100% identical among members of the Ebola viral isolates’ 33, and Ala238, Gln241, Leu242, Val245, Ile246, Leu249 which interacts with a β sheet to create a hydrophobic subdomain 33. This helix is marked in magenta in Figure 3b, and the Edmundson wheel is shown in Figure 3c. Recently, antifiloviral compounds were shown to bind and inhibit the polymerase cofactor activity of VP35 37. Figure 3d shows one of the compounds (1D5) in complex with VP35 (PDBid:4IBFA). It can be seen that atoms in the compounds make hydrogen bonds with residues on the AH spanning residues 238–252 ( Table 5). These structures were used to derive a receptor-ligand pharmacophore, which was found to have similar features to the ligand based pharmacophore derived from four FDA approved drugs that inhibit the Ebola virus 38. Once again, we demonstrate that unique values of an AH is a strong indicator of its significance in the viral functionality.
Table 5. VP35 (PDBid:4IBFA) in complex with a component (1D5) that inhibits its polymerase cofactor activity.
VP35 atom | 1D5 atom | Dist (Å) | Interaction type |
---|---|---|---|
LYS/251/NZ
GLN/241/NE2 ASP/302/O LYS/251/CD LYS/251/CE GLN/244/OE1 ALA/221/CB GLN/241/OE1 GLN/241/CD GLN/244/NE2 |
OAD
OAB CLA OAD OAD CAM OAA OAB OAB OAB |
2.6
2.7 3.0 3.2 3.3 3.3 3.5 3.5 3.5 3.5 |
HBond
HBond HPhobic HPhobic HPhobic HPhobic HPhobic HBond HPhobic HBond |
Multifunctional/moonlighting
The multifunctional roles played by many of these Ebola proteins is probably due to stretches of intrinsically disordered regions within the structure - ‘fuzzy objects with fuzzy structures and fuzzy functions’ 39. The conformational plasticity 9 and moonlighting abilities of these proteins are key determinants for immune evasion 40.
The above examples have analyzed all helices from the Ebola proteome. However, it also possible to analyze the helices in a single protein, and probe those for unique features. Table 6 shows the values obtained from PAGAL for helices of the C-terminal domain of the Zaire Ebola virus nucleoprotein 41. It can be seen that 4QAZA.HELIX0 (residues 646-658) has a reasonably high hydrophobic moment (although it will not rank highly if we analyze all helices present in this proteome), and also a high number of charged residues ( Figure 4a,b). It has been observed that ‘the side chains of Glu645, His646, Glu649, Lys684, Glu695, Glu709, Lys728 and Gln739 are partly disordered so that some or all of their atoms are not visible in the electron density’ 41. Glu645, His646, Glu649 are part of this helix, and are thus critical to the disorderedness of the protein, which is critical for its moonlighting roles. Note, that Glu has been observed to be the second most disorder promoting residue (after proline) 42. Furthermore, Tyr652 and Leu656, which lie in this helix, are residues that have been hypothesized to be part of the protein-protein interaction site involving this protein 41.
Table 6. Properties of the helices of the C-terminal domain of the Zaire Ebola virus nucleoprotein (PDBid:4QAZA).
Helix | Len | HM | RPNR | NCH |
---|---|---|---|---|
4QAZA.HELIX0
4QAZA.HELIX1 4QAZA.HELIX2 4QAZA.HELIX3 4QAZA.HELIX4 4QAZA.HELIX5 4QAZA.HELIX6 |
13
12 3 3 4 3 11 |
8.4
0.8 2.5 2.4 1.8 0.1 2.1 |
0.7
0.7 0 0 0.3 -1 1 |
6
3 1 1 3 0 4 |
Conclusions
The ability of a genome as small as the Ebola virus to inflict a dishearteningly high percentage of mortality in human subjects is a humbling experience in the context of the tremendous technological advancements achieved in the last few decades 3, 4. The Ebola virus potently suppresses the human immune response 2, 6, 43 by binding with key human proteins involved in the immune pathway 18. These protein-protein interactions are often mediated through well structured secondary regions within the protein structures (alpha helices), and the design of molecules that inhibit these ‘hotspots’ 20, 44 has been a well known strategy to develop drugs to counter bacterial and viral infections 10– 12. For example, synthetic peptides derived from the oligomerization domain of polymerase subunits has been shown to inhibit viral proteins 45, 46. In addition, there might exist other protein domains that might be exploited by non-native viral peptides to obstruct viral functionality. In the current work, we characterize alpha helices in the Ebola virus proteome using a recently implemented open access software (PAGAL) 14, thus identifying potential targets for inhibition of the helix mediated interactions. Through several examples, we demonstrate that helices with unique features are involved in interactions with host proteins (either antibodies from survivors, or proteins regulating the immune response). Further, we also provide an alternate way of analyzing differences in related proteins (from the Marburg virus) by focusing on the properties of corresponding helices. As future work, we intend to develop methodologies to design peptides that would target these ‘hotspots’ 44. It has to be kept in mind that it has been a challenge to design small ligands that disrupt protein-protein interactions, and designers resort to several innovative techniques to overcome thermodynamic instability or proteolytic susceptibility 47– 50. These helices can essentially be epitopes 51, 52 for developing antibodies against the virus 53, 54. Interestingly, ZMapp, a cocktail of three antibodies has shown reversion of advanced Ebola symptoms in non-human primates 55, and uses only glycoprotein-specific epitope generated antibodies 52, 56. It is interesting to hypothesize that additions to this cocktail with antibodies derived from other epitopes (for example, 4U2XA.HELIX5 from VP24 that is involved in immune response suppression) could prove more effective. Thus, we provide a comprehensive list of potential targets within the small proteome of the Ebola virus that can directed rational design to quickly innovate therapies.
Funding Statement
AMD wishes to acknowledge grant support from the California Department of Food and Agriculture PD/GWSS Board. BJ acknowledges financial support from Tata Institute of Fundamental Research (Department of Atomic Energy). Additionally, BJR is thankful to the Department of Science and Technology for the JC Bose Award Grant. BA acknowledges financial support from the Science Institute of the University of Iceland.
v3; ref status: indexed
References
- 1.Pattyn S, van der Groen G, Courteille G, et al. : Isolation of Marburg-like virus from a case of haemorrhagic fever in Zaire. Lancet. 1977;1(8011):573–574. 10.1016/S0140-6736(77)92002-5 [DOI] [PubMed] [Google Scholar]
- 2.Colebunders R, Borchert M: Ebola haemorrhagic fever–a review. J Infect. 2000;40(1):16–20. 10.1053/jinf.1999.0603 [DOI] [PubMed] [Google Scholar]
- 3.Piot P: Ebola’s perfect storm. Science. 2014;345(6202):1221. 10.1126/science.1260695 [DOI] [PubMed] [Google Scholar]
- 4.Piot P, Muyembe JJ, Edmunds WJ: Ebola in west Africa: from disease outbreak to humanitarian crisis. Lancet Infect Dis. 2014;14(11):1034–1035. 10.1016/S1473-3099(14)70956-9 [DOI] [PubMed] [Google Scholar]
- 5.Kiley M, Bowen E, Eddy G, et al. : Filoviridae: a taxonomic home for Marburg and Ebola Viruses? Intervirology. 1982;18(1–2):24–32. 10.1159/000149300 [DOI] [PubMed] [Google Scholar]
- 6.Daugherty MD, Malik HS: How a virus blocks a cellular emergency access lane to the nucleus, STAT! Cell Host Microbe. 2014;16(2):150–152. 10.1016/j.chom.2014.07.013 [DOI] [PubMed] [Google Scholar]
- 7.Elliott LH, Kiley MP, McCormick JB: Descriptive analysis of Ebola virus proteins. Virology. 1985;147(1):169–176. 10.1016/0042-6822(85)90236-3 [DOI] [PubMed] [Google Scholar]
- 8.Bornholdt ZA, Noda T, Abelson DM, et al. : Structural basis for ebolavirus matrix assembly and budding; protein plasticity allows multiple functions. Cell. 2013;154:763. 10.1016/j.cell.2013.07.015 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9.Radzimanowski J, Effantin G, Weissenhorn W: Conformational plasticity of the Ebola virus matrix protein. Protein Sci. 2014;23(11):1519–1527. 10.1002/pro.2541 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10.Wild CT, Shugars DC, Greenwell TK, et al. : Peptides corresponding to a predictive alpha-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection. Proc Natl Acad Sci U S A. 1994;91(21):9770–9774. 10.1073/pnas.91.21.9770 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11.Judice JK, Tom JY, Huang W, et al. : Inhibition of HIV type 1 infectivity by constrained alpha-helical peptides: implications for the viral fusion mechanism. Proc Natl Acad Sci U S A. 1997;94(25):13426–13430. 10.1073/pnas.94.25.13426 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12.Ernst JT, Kutzki O, Debnath AK, et al. : Design of a protein surface antagonist based on α-helix mimicry: inhibition of gp41 assembly and viral fusion. Angew Chem Int Ed Engl. 2002;41(2):278–281. [DOI] [PubMed] [Google Scholar]
- 13.Jones MK, Anantharamaiah GM, Segrest JP: Computer programs to identify and classify amphipathic alpha helical domains. J Lipid Res. 1992;33(2):287–296. [PubMed] [Google Scholar]
- 14.Chakraborty S, Rao B, Dandekar A: Pagal - Properties and corresponding graphics of alpha helical structures in proteins [v2; ref status: indexed, http://f1000r.es/4e7]. F1000Res. 2014;3:206. 10.12688/f1000research.4952.2 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 15.Joosten RP, te Beek TA, Krieger E, et al. : A series of PDB related databases for everyday needs. Nucleic Acids Res. 2011;39(Database issue):D411–419. 10.1093/nar/gkq1105 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 16.Weissenhorn W, Carfi A, Lee KH, et al. : Crystal structure of the Ebola virus membrane fusion subunit, GP2, from the envelope glycoprotein ectodomain. Mol Cell. 1998;2(5):605–616. 10.1016/S1097-2765(00)80159-8 [DOI] [PubMed] [Google Scholar]
- 17.Lee JE, Fusco ML, Hessell AJ, et al. : Structure of the Ebola virus glycoprotein bound to an antibody from a human survivor. Nature. 2008;454(7201):177–182. 10.1038/nature07082 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 18.Xu W, Edwards MR, Borek DM, et al. : Ebola virus VP24 targets a unique NLS binding site on karyopherin alpha 5 to selectively compete with nuclear import of phosphorylated STAT1. Cell Host Microbe. 2014;16(2):187–200. 10.1016/j.chom.2014.07.008 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 19.Reid SP, Leung LW, Hartman AL, et al. : Ebola virus VP24 binds karyopherin alpha1 and blocks STAT1 nuclear accumulation. J Virol. 2006;80(11):5156–5167. 10.1128/JVI.02349-05 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 20.Azzarito V, Long K, Murphy NS, et al. : Inhibition of α-helix-mediated protein-protein interactions using designed molecules. Nat Chem. 2013;5(3):161–173. 10.1038/nchem.1568 [DOI] [PubMed] [Google Scholar]
- 21.Suzuki Y, Gojobori T: The origin and evolution of Ebola and Marburg viruses. Mol Biol Evol. 1997;14(8):800–806. 10.1093/oxfordjournals.molbev.a025820 [DOI] [PubMed] [Google Scholar]
- 22.Feldmann H, Nichol ST, Klenk HD, et al. : Characterization of filoviruses based on differences in structure and antigenicity of the virion glycoprotein. Virology. 1994;199(2):469–473. 10.1006/viro.1994.1147 [DOI] [PubMed] [Google Scholar]
- 23.Larkin MA, Blackshields G, Brown NP, et al. : Clustal W and Clustal X version 2.0. Bioinformatics. 2007;23(21):2947–2948. 10.1093/bioinformatics/btm404 [DOI] [PubMed] [Google Scholar]
- 24.Gouy M, Guindon S, Gascuel O: SeaView version 4: A multiplatform graphical user interface for sequence alignment and phylogenetic tree building. Mol Biol Evol. 2010;27(2):221–224. 10.1093/molbev/msp259 [DOI] [PubMed] [Google Scholar]
- 25.Konagurthu AS, Whisstock JC, Stuckey PJ, et al. : MUSTANG: a multiple structural alignment algorithm. Proteins. 2006;64(3):559–574. 10.1002/prot.20921 [DOI] [PubMed] [Google Scholar]
- 26.Badani H, Garry RF, Wimley WC: Peptide entry inhibitors of enveloped viruses: the importance of interfacial hydrophobicity. Biochim Biophys Acta. 2014;1838(9):2180–97. 10.1016/j.bbamem.2014.04.015 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 27.Weissenhorn W, Calder LJ, Wharton SA, et al. : The central structural feature of the membrane fusion protein subunit from the Ebola virus glycoprotein is a long triple-stranded coiled coil. Proc Natl Acad Sci U S A. 1998;95(11):6032–6036. 10.1073/pnas.95.11.6032 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 28.Zhang AP, Bornholdt ZA, Liu T, et al. : The Ebola virus interferon antagonist VP24 directly binds STAT1 and has a novel, pyramidal fold. PLoS Pathog. 2012;8(2):e1002550. 10.1371/journal.ppat.1002550 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 29.Chakraborty S, Rao B, Asgeirsson B, et al. : Correlating the ability of VP24 protein from Ebola and Marburg viruses to bind human karyopherin to their immune suppression mechanism and pathogenicity using computational methods [v1; ref status: awaiting peer review, http://f1000r.es/4o3]. F1000Res. 2014;3:265 10.12688/f1000research.5666.1 [DOI] [Google Scholar]
- 30.Miranda ME, White ME, Dayrit MM, et al. : Seroepidemiological study of filovirus related to Ebola in the Philippines. Lancet. 1991;337(8738):425–426. 10.1016/0140-6736(91)91199-5 [DOI] [PubMed] [Google Scholar]
- 31.Miranda ME, Miranda NL: Reston Ebolavirus in humans and animals in the Philippines: a review. J Infect Dis. 2011;204(Suppl 3):S757–S760. 10.1093/infdis/jir296 [DOI] [PubMed] [Google Scholar]
- 32.Valmas C, Grosch MN, Schumann M, et al. : Marburg virus evades interferon responses by a mechanism distinct from Ebola virus. PLoS Pathog. 2010;6(1):e1000721. 10.1371/journal.ppat.1000721 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 33.Leung DW, Ginder ND, Fulton DB, et al. : Structure of the Ebola VP35 interferon inhibitory domain. Proc Natl Acad Sci U S A. 2009;106(2):411–416. 10.1073/pnas.0807854106 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 34.Kimberlin CR, Bornholdt ZA, Li S, et al. : Ebolavirus VP35 uses a bimodal strategy to bind dsRNA for innate immune suppression. Proc Natl Acad Sci U S A. 2010;107(1):314–319. 10.1073/pnas.0910547107 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 35.Steegborn C, Danot O, Huber R, et al. : Crystal structure of transcription factor malt domain iii: a novel helix repeat fold implicated in regulated oligomerization. Structure. 2001;9(11):1051–1060. 10.1016/S0969-2126(01)00665-7 [DOI] [PubMed] [Google Scholar]
- 36.Subbotina E, Dadaeva A, Kachko A, et al. : Genetic factors of Ebola virus virulence in guinea pigs. Virus Res. 2010;153(1):121–133. 10.1016/j.virusres.2010.07.015 [DOI] [PubMed] [Google Scholar]
- 37.Brown CS, Lee MS, Leung DW, et al. : In silico derived small molecules bind the filovirus VP35 protein and inhibit its polymerase cofactor activity. J Mol Biol. 2014;426(10):2045–2048. 10.1016/j.jmb.2014.01.010 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 38.Ekins S, Freundlich JS, Coffee DW: A common feature pharmacophore for FDA-approved drugs inhibiting the Ebola virus [v2; ref status: indexed, http://f1000r.es/4wt]. F1000 Res. 2014;3:277 10.12688/f1000research.5741.2 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 39.Uversky VN: Intrinsically disordered proteins from A to Z. Int J Biochem Cell Biol. 2011;43(8):1090–1103. 10.1016/j.biocel.2011.04.001 [DOI] [PubMed] [Google Scholar]
- 40.Cook JD, Lee JE: The secret life of viral entry glycoproteins: moonlighting in immune evasion. PLoS Pathog. 2013;9(5):e1003258. 10.1371/journal.ppat.1003258 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 41.Dziubanska PJ, Derewenda U, Ellena JF, et al. : The structure of the C-terminal domain of the Zaire ebolavirus nucleoprotein. Acta Crystallogr D Biol Crystallogr. 2014;70(Pt 9):2420–2429. 10.1107/S1399004714014710 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 42.Uversky VN: The alphabet of intrinsic disorder: II. various roles of glutamic acid in ordered and intrinsically disordered proteins. Intrinsically Disord Proteins. 2013;1:18–40 10.4161/idp.24684 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 43.Kash JC, Mϋhlberger E, Carter V, et al. : Global suppression of the host antiviral response by Ebola- and Marburgviruses: increased antagonism of the type i interferon response is associated with enhanced virulence. J Virol. 2006;80(6):3009–3020. 10.1128/JVI.80.6.3009-3020.2006 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 44.Wells JA, McClendon CL: Reaching for high-hanging fruit in drug discovery at protein-protein interfaces. Nature. 2007;450(7172):1001–1009. 10.1038/nature06526 [DOI] [PubMed] [Google Scholar]
- 45.Hartlieb B, Modrof J, Mϋhlberger E, et al. : Oligomerization of Ebola virus VP30 is essential for viral transcription and can be inhibited by a synthetic peptide. J Biol Chem. 2003;278(43):41830–41836. 10.1074/jbc.M307036200 [DOI] [PubMed] [Google Scholar]
- 46.Ghanem A, Mayer D, Chase G, et al. : Peptide-mediated interference with influenza A virus polymerase. J Virol. 2007;81(14):7801–7804. 10.1128/JVI.00724-07 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 47.Chapman RN, Dimartino G, Arora PS: A highly stable short alpha-helix constrained by a main-chain hydrogen-bond surrogate. J Am Chem Soc. 2004;126(39):12252–12253. 10.1021/ja0466659 [DOI] [PubMed] [Google Scholar]
- 48.Bird GH, Madani N, Perry AF, et al. : Hydrocarbon double-stapling remedies the proteolytic instability of a lengthy peptide therapeutic. Proc Natl Acad Sci U S A. 2010;107(32):14093–14098. 10.1073/pnas.1002713107 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 49.Bird GH, Boyapalle S, Wong T, et al. : Mucosal delivery of a double-stapled RSV peptide prevents nasopulmonary infection. J Clin Invest. 2014;124(5):2113–24. 10.1172/JCI71856 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 50.Harrison RS, Shepherd NE, Hoang HN, et al. : Downsizing human, bacterial, and viral proteins to short water-stable alpha helices that maintain biological potency. Proc Natl Acad Sci U S A. 2010;107(26):11686–11691. 10.1073/pnas.1002498107 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 51.Takada A, Feldmann H, Stroeher U, et al. : Identification of protective epitopes on Ebola virus glycoprotein at the single amino acid level by using recombinant vesicular stomatitis viruses. J Virol. 2003;77(2):1069–1074. 10.1128/JVI.77.2.1069-1074.2003 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 52.Wilson JA, Hevey M, Bakken R, et al. : Epitopes involved in antibody-mediated protection from Ebola virus. Science. 2000;287(5458):1664–1666. 10.1126/science.287.5458.1664 [DOI] [PubMed] [Google Scholar]
- 53.Takada A, Ebihara H, Jones S, et al. : Protective efficacy of neutralizing antibodies against Ebola Virus infection. Vaccine. 2007;25(6):993–999. 10.1016/j.vaccine.2006.09.076 [DOI] [PubMed] [Google Scholar]
- 54.Qiu X, Alimonti JB, Melito PL, et al. : Characterization of Zaire ebolavirus glycoprotein-specific monoclonal antibodies. Clin Immunol. 2011;141(2):218–227. 10.1016/j.clim.2011.08.008 [DOI] [PubMed] [Google Scholar]
- 55.Qiu X, Wong G, Audet J, et al. : Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp. Nature. 2014;514(7520):47–53. 10.1038/nature13777 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 56.Olinger GG, Jr, Pettitt J, Kim D, et al. : Delayed treatment of Ebola virus infection with plant-derived monoclonal antibodies provides protection in rhesus macaques. Proc Natl Acad Sci U S A. 2012;109(44):18030–18035. 10.1073/pnas.1213709109 [DOI] [PMC free article] [PubMed] [Google Scholar]